BG66330B1 - Бензоилгуанидинова сол - Google Patents

Бензоилгуанидинова сол Download PDF

Info

Publication number
BG66330B1
BG66330B1 BG108065A BG10806503A BG66330B1 BG 66330 B1 BG66330 B1 BG 66330B1 BG 108065 A BG108065 A BG 108065A BG 10806503 A BG10806503 A BG 10806503A BG 66330 B1 BG66330 B1 BG 66330B1
Authority
BG
Bulgaria
Prior art keywords
pyrrolylcarbonyl
trifluoromethyl
benzoylguanidine
compound
piperazinyl
Prior art date
Application number
BG108065A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG108065A (bg
Inventor
ChristianEickmeier Christian Eickmeier
PeterSieger Peter Sieger
VolkmarKorner Volkmar Korner
RolfHerter Rolf Herter
WernerRall Werner Rall
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co. Kgboehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh & Co. Kgboehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co. Kgboehringer Ingelheim Pharma Gmbh & Co. Kg
Publication of BG108065A publication Critical patent/BG108065A/bg
Publication of BG66330B1 publication Critical patent/BG66330B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BG108065A 2001-02-15 2003-08-06 Бензоилгуанидинова сол BG66330B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10106970A DE10106970A1 (de) 2001-02-15 2001-02-15 Neues Benzoylguanidinsalz
PCT/EP2002/001535 WO2002064563A1 (de) 2001-02-15 2002-02-14 Neues benzoylguanidinsalz

Publications (2)

Publication Number Publication Date
BG108065A BG108065A (bg) 2005-01-31
BG66330B1 true BG66330B1 (bg) 2013-06-28

Family

ID=7674094

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108065A BG66330B1 (bg) 2001-02-15 2003-08-06 Бензоилгуанидинова сол

Country Status (31)

Country Link
US (2) US20080025919A1 (cg-RX-API-DMAC7.html)
EP (1) EP1362030B1 (cg-RX-API-DMAC7.html)
JP (3) JP4408626B2 (cg-RX-API-DMAC7.html)
KR (1) KR100862176B1 (cg-RX-API-DMAC7.html)
CN (1) CN1222510C (cg-RX-API-DMAC7.html)
AT (1) ATE553078T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002250939B2 (cg-RX-API-DMAC7.html)
BG (1) BG66330B1 (cg-RX-API-DMAC7.html)
BR (1) BR0207867A (cg-RX-API-DMAC7.html)
CA (1) CA2434829C (cg-RX-API-DMAC7.html)
CY (1) CY1112878T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ303277B6 (cg-RX-API-DMAC7.html)
DE (1) DE10106970A1 (cg-RX-API-DMAC7.html)
DK (1) DK1362030T3 (cg-RX-API-DMAC7.html)
EA (1) EA006245B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP034708A (cg-RX-API-DMAC7.html)
EE (1) EE200300393A (cg-RX-API-DMAC7.html)
ES (1) ES2385472T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20030653B1 (cg-RX-API-DMAC7.html)
HU (1) HU230035B1 (cg-RX-API-DMAC7.html)
IL (1) IL156934A (cg-RX-API-DMAC7.html)
NO (1) NO20033299D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ528081A (cg-RX-API-DMAC7.html)
PL (1) PL213300B1 (cg-RX-API-DMAC7.html)
PT (1) PT1362030E (cg-RX-API-DMAC7.html)
RS (1) RS52014B (cg-RX-API-DMAC7.html)
SI (1) SI1362030T1 (cg-RX-API-DMAC7.html)
SK (1) SK287830B6 (cg-RX-API-DMAC7.html)
UA (1) UA74625C2 (cg-RX-API-DMAC7.html)
WO (1) WO2002064563A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200305365B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10106970A1 (de) * 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma Neues Benzoylguanidinsalz
DE10144030A1 (de) * 2001-09-07 2003-03-27 Boehringer Ingelheim Pharma Verbesserung der lokalen Verträglichkeit bei intravenöser Verabreichung von 4-(4-(2-Pyrrolylcarbonyl-1-piperazinyl)-3-trifluormethyl-benzoylguanidin
US6982256B2 (en) 2001-09-07 2006-01-03 Boehringer Ingelheim Pharma Kg Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration
US20110118262A1 (en) * 2008-07-08 2011-05-19 Boehringer Ingelheim International Gmbh Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors
US10405746B2 (en) * 2014-04-14 2019-09-10 The University Of Memphis Research Foundation Wireless analog passive sensors
US12369831B1 (en) 2018-04-30 2025-07-29 Bashir I. Morshed Apparatus and method to capture body signals with conjugate coils and paired coils

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19601303A1 (de) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln
DE19843489B4 (de) * 1998-09-22 2006-12-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Benzoylguanidin-Abkömmlinge mit vorteilhaften Eigenschaften, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln, sowie diese enthaltende pharmazeutische Zubereitung
US6323207B1 (en) * 1998-09-22 2001-11-27 Boehringer Ingelheim Pharma Kg Benzoylguanidine derivatives
DE10106970A1 (de) * 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma Neues Benzoylguanidinsalz
US6730678B2 (en) * 2001-02-15 2004-05-04 Boehringer Ingelheim Pharma Kg Benzoylguanidine salt and hydrates thereof

Also Published As

Publication number Publication date
NO20033299L (no) 2003-07-22
HK1064093A1 (zh) 2005-01-21
RS52014B (sr) 2012-04-30
EP1362030A1 (de) 2003-11-19
JP2009235097A (ja) 2009-10-15
CN1491213A (zh) 2004-04-21
CA2434829C (en) 2009-12-08
BR0207867A (pt) 2004-03-23
IL156934A0 (en) 2004-02-08
BG108065A (bg) 2005-01-31
EE200300393A (et) 2003-12-15
JP2013107906A (ja) 2013-06-06
SK10202003A3 (sk) 2004-02-03
DK1362030T3 (da) 2012-07-09
UA74625C2 (en) 2006-01-16
CA2434829A1 (en) 2002-08-22
PL213300B1 (pl) 2013-02-28
EP1362030B1 (de) 2012-04-11
IL156934A (en) 2005-12-18
AU2002250939B2 (en) 2007-09-06
JP5745215B2 (ja) 2015-07-08
ZA200305365B (en) 2004-04-22
PT1362030E (pt) 2012-07-04
PL362129A1 (en) 2004-10-18
NO20033299D0 (no) 2003-07-22
CZ303277B6 (cs) 2012-07-11
EA006245B1 (ru) 2005-10-27
CZ20032210A3 (cs) 2003-12-17
SI1362030T1 (sl) 2012-07-31
SK287830B6 (sk) 2011-11-04
HRP20030653A2 (en) 2005-06-30
HRP20030653B1 (en) 2012-06-30
JP2004518721A (ja) 2004-06-24
ATE553078T1 (de) 2012-04-15
HUP0303027A2 (hu) 2003-12-29
EA200300771A1 (ru) 2004-02-26
US20080025919A1 (en) 2008-01-31
ECSP034708A (es) 2003-12-24
KR20030075197A (ko) 2003-09-22
NZ528081A (en) 2005-10-28
JP4408626B2 (ja) 2010-02-03
CN1222510C (zh) 2005-10-12
US20080241077A1 (en) 2008-10-02
HU230035B1 (hu) 2015-05-28
YU61503A (sh) 2006-05-25
HUP0303027A3 (en) 2010-04-28
WO2002064563A1 (de) 2002-08-22
KR100862176B1 (ko) 2008-10-09
DE10106970A1 (de) 2002-08-29
CY1112878T1 (el) 2016-04-13
ES2385472T3 (es) 2012-07-25

Similar Documents

Publication Publication Date Title
CN101535311B (zh) 吡咯并嘧啶酮衍生物的盐及其制备方法
EP2038282B1 (en) Salts of pyrrolopyrimidinone derivatives and process for preparing the same
US20080241077A1 (en) Benzoylguanidine salt and hydrates thereof
JP3853389B2 (ja) 新規の3−フェニルスルホニル−3,7−ジアザビシクロ[3,3,1]ノナン−化合物、その製法及び抗不整脈剤
US6730678B2 (en) Benzoylguanidine salt and hydrates thereof
HK1064093B (en) Benzoylguanidine salt
MXPA03007192A (en) Novel benzoylguanidine salt
HK1135095A (en) Salts of pyrrolopyrimidinone derivatives and process for preparing the same
HK1175780A1 (en) Crystalline cdc7 inhibitor salts
HK1175780B (en) Crystalline cdc7 inhibitor salts